Teprotumumab

From WikiMD.org
Jump to navigation Jump to search

Teprotumumab

Teprotumumab (pronunciation: te-pro-tu-mu-mab) is a fully human monoclonal antibody that is used for the treatment of thyroid eye disease (TED). It is marketed under the brand name Tepezza by Horizon Therapeutics.

Etymology

The name Teprotumumab is derived from the International Nonproprietary Names (INN), where 'te' stands for therapeutic, 'pro' indicates the target (in this case, the insulin-like growth factor 1 receptor), 'tu' is the source (human), and 'mab' is indicative of its monoclonal antibody nature.

Mechanism of Action

Teprotumumab works by binding to the insulin-like growth factor 1 receptor (IGF-1R) on cells. This binding inhibits the activation of the receptor, which in turn reduces the symptoms of thyroid eye disease such as inflammation and tissue expansion.

Related Terms

See Also

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski